共 50 条
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report
被引:4
作者:
Kattan, Joseph
[1
]
Kattan, Clarisse
[1
]
Farhat, Fadi
[2
]
Assi, Tarek
[2
,3
]
机构:
[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
[2] Hammoud Hosp UMC, Hematol Oncol Dept, Saida, Lebanon
[3] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
关键词:
binimetinib;
BRAF;
encorafenib;
immune checkpoint;
MEK;
melanoma;
resistance;
METASTATIC MELANOMA;
MUTANT MELANOMA;
OPEN-LABEL;
NIVOLUMAB;
COMBINATION;
DABRAFENIB;
TRAMETINIB;
IPILIMUMAB;
EFFICACY;
STANDARD;
D O I:
10.1097/CAD.0000000000000827
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.
引用
收藏
页码:1052 / 1054
页数:3
相关论文
共 50 条